tbuckley/cabot-search huggingface dataset:
Pharmacological inhibition of MDM4 alleviates pulmonary fibrosis
Authors: Qianru Mei, Zhenhua Yang, Zhengkai Xiang, He Zuo, Zijing Zhou, Xiaochuan Dong, Ludan Zhang, Wenhui Song, Yi Wang, Qinghua Hu, Yong Zhou, Jing Qu
Journal: Theranostics (2023)

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease of unknown etiology with no cure.A better understanding of the disease processes and identification of druggable targets will benefit the development of effective therapies for IPF.We previously reported that MDM4 promoted lung fibrosis through the MDM4-p53-dependent pathway.However, it remained unclear whether targeting this pathway would have any therapeutic potential.In this study, we evaluated the efficacy of XI-011, a small molecular inhibitor of MDM4, for treating lung fibrosis.We found that XI-011 significantly reduced MDM4 expression and increased the expression of total and acetylated p53 in primary human myofibroblasts and a murine fibrotic model.XI-011 treatment resulted in the resolution of lung fibrosis in mice with no notable impact on normal fibroblast death or the morphology of healthy lungs.Based on these findings, we propose that XI-011 might be a promising therapeutic drug candidate for treating pulmonary fibrosis.
“Care Bundle” Improved Outcomes for Patients With Brain Bleeds
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnostic and Prognostic Value of Stress Cardiovascular Magnetic Resonance Imaging in Patients With Known or Suspected Coronary Artery Disease
Authors: Fabrizio Ricci, Mohammed Y. Khanji, Giandomenico Bisaccia, Alberto Cipriani, Annamaria Di Cesare, Laura Ceriello, Cesare Mantini, Marco Zimarino, Artur Fedorowski, Sabina Gallina, Steffen E. Petersen, Chiara Bucciarelli-Ducci
Journal: JAMA Cardiology (2023)

The clinical utility of stress cardiovascular magnetic resonance imaging (CMR) in stable chest pain is still debated, and the low-risk period for adverse cardiovascular (CV) events after a negative test result is unknown.
Gender disparity in Canadian Institutes of Health Research grant funding decisions among recipients from dermatology departments: a retrospective study
Authors: Brendan Tao, Jeffrey Ding, Marissa Joseph, Chi-Wei Tien, Sahil Chawla, Waleed Khan, Faisal Khosa
Journal: British Journal of Dermatology (2023)

We investigated the extent of gender disparity among dermatologists awarded Canadian Institutes of Health Research (CIHR) grants. Our results indicate that, between 2008 and 2022, CIHR grant recipients were disproportionately male, thereby substantiating the influence of system-level barriers during research funding decision-making.
Mutations in the gene encoding peroxisomal α-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy
Authors: Sacha Ferdinandusse, Simone Denis, Peter T. Clayton, Andrew Graham, John E. Rees, John T. Allen, Brendan N. McLean, Ann Y. Brown, Peter Vreken, Hans R. Waterham, Ronald J.A. Wanders
Journal: Nature Genetics (2000)
Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy
Authors: Cuifang Zheng, Mingbin Zheng, Ping Gong, Jizhe Deng, Huqiang Yi, Pengfei Zhang, Yijuan Zhang, Peng Liu, Yifan Ma, Lintao Cai
Journal: Biomaterials (2013)
3D Printed Chondrogenic Functionalized PGS Bioactive Scaffold for Cartilage Regeneration
Authors: Sinan Wang, Bin Luo, Baoshuai Bai, Qianyi Wang, Hongying Chen, Xiaoyan Tan, Zhengya Tang, Sisi Shen, Hengxing Zhou, Zhengwei You, Guangdong Zhou, Dong Lei
Journal: Advanced Healthcare Materials (2023)

Tissue engineering is emerging as a promising approach for cartilage regeneration and repair. Endowing scaffolds with cartilaginous bioactivity to obtain bionic microenvironment and regulating the matching of scaffold degradation and regeneration play a crucial role in cartilage regeneration. Poly(glycerol sebacate) (PGS) is a representative thermosetting bioelastomer known for its elasticity, biodegradability, and biocompatibility and is widely used in tissue engineering. However, the modification and drug loading of the PGS scaffold is still a key challenge due to its high temperature curing conditions and limited reactive groups, which seriously hinders its further functional application. Here, a simple versatile new strategy of super swelling-absorption and cross-linked networks locking is presented to successfully create the 3D printed PGS-CS/Gel scaffold for the first time based on FDA-approved PGS, gelatin (Gel) and chondroitin sulfate (CS). The PGS-CS/Gel scaffold exhibits the desirable synergistic properties of well-organized hierarchical structures, excellent elasticity, improved hydrophilicity, and cartilaginous bioactivity, which can promote the adhesion, proliferation, and migration of chondrocytes. Importantly, the rate of cartilage regeneration can be well-matched with degradation of PGS-CS/Gel scaffold, and achieve uniform and mature cartilage tissue without scaffold residual. The bioactive scaffold can successfully repair cartilage in a rabbit trochlear groove defect model indicating a promising prospect of clinical transformation.
Managing mpox using a remote monitoring service
Authors: Michael Rayment, Stephen Cole, Joseph Heskin, Sadia Khan, Mike Wright, Jodian Barrett, James Bird, Christopher Scott, Ruth Byrne, Nicolo Girometti, Olamide Dosekun, John McSorley, Gabriel Wallis, Lauren Bull, Paul Randell, Nabeela Mughal, Luke S P Moore, Gary W Davies, Rachael Jones
Journal: Journal of Infection (2023)
SARS-CoV-2 infection induces long-lived B and T-cell responses up to 15 months post-infection, irrespective of disease severity
Authors: Kristin G.-I. Mohn, Geir Bredholt, Therese Bredholt Onyango, Karl A. Brokstad, Fan Zhou, Jan Cato Holter, Kristian Tonby, Anne Ma Dyrhol-Riise, Rebecca Jane Cox
Journal: Journal of Infection (2023)
Front Cover Image, Volume 43, Issue 4
Authors: Jessica Merjane, Roger Chung, Rickie Patani, Leszek Lisowski
Journal: Medicinal Research Reviews (2023)

The cover image is based on the Review Article Molecular mechanisms of amyotrophic lateral sclerosis as broad therapeutic targets for gene therapy applications utilizing adeno-associated viral vectors by Jessica Merjane et al., https://doi.org/10.1002/med.21937.
Blood Gene Expression and Immune Cell Subtypes Associated with Chronic Obstructive Pulmonary Disease Exacerbations
Authors: Min Hyung Ryu, Jeong H. Yun, Jarrett D. Morrow, Aabida Saferali, Peter Castaldi, Robert Chase, Meryl Stav, Zhonghui Xu, Igor Barjaktarevic, MeiLan Han, Wassim Labaki, Yvonne J. Huang, Stephanie Christenson, Wanda O’Neal, Russell Bowler, Don D. Sin, Christine M. Freeman, Jeffrey L. Curtis, Craig P. Hersh
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

Acute exacerbations of chronic obstructive pulmonary disease (AE-COPDs) are associated with a significant disease burden. Blood immune phenotyping may improve our understanding of a COPD endotype at increased risk of exacerbations.
The influence of the “cancer” label on perceptions and management decisions for low-grade prostate cancer
Authors: Alejandro Berlin, Matthew Ramotar, Anna T Santiago, Zhihui Liu, Joyce Li, Howard Wolinsky, Christopher J D Wallis, Melvin L K Chua, Gladell P Paner, Theodorus van der Kwast, Matthew R Cooperberg, Andrew J Vickers, David R Urbach, Scott E Eggener
Journal: JNCI Journal of the National Cancer Institute (2023)

Abstract Background Grade Group 1 (GG1) prostate cancer should be managed with active surveillance (AS). Global uptake of AS remains disappointingly slow and heterogeneous. Removal of cancer labels has been proposed to reduce GG1 overtreatment. We sought to determine the impact of GG1 disease terminology on individual’s perceptions and decision making. Methods Discrete choice experiments were conducted on 3 cohorts: healthy men, canonical partners (partners), and patients with GG1 (patients). Participants reported preferences in a series of vignettes with 2 scenarios each, permuting key opinion leader–endorsed descriptors: biopsy (adenocarcinoma, acinar neoplasm, prostatic acinar neoplasm of low malignant potential [PAN-LMP], prostatic acinar neoplasm of uncertain malignant potential), disease (cancer, neoplasm, tumor, growth), management decision (treatment, AS), and recurrence risk (6%, 3%, 1%, &amp;lt;1%). Influence on scenario selection were estimated by conditional logit models and marginal rates of substitution. Two additional validation vignettes with scenarios portraying identical descriptors except the management options were embedded into the discrete choice experiments. Results Across cohorts (194 healthy men, 159 partners, and 159 patients), noncancer labels PAN-LMP or prostatic acinar neoplasm of uncertain malignant potential and neoplasm, tumor, or growth were favored over adenocarcinoma and cancer (P &amp;lt; .01), respectively. Switching adenocarcinoma and cancer labels to PAN-LMP and growth, respectively, increased AS choice by up to 17%: healthy men (15%, 95% confidence interval [CI] = 10% to 20%, from 76% to 91%, P &amp;lt; .001), partners (17%, 95% CI = 12% to 24%, from 65% to 82%, P &amp;lt; .001), and patients (7%, 95% CI = 4% to 12%, from 75% to 82%, P = .063). The main limitation is the theoretical nature of questions perhaps leading to less realistic choices. Conclusions “Cancer” labels negatively affect perceptions and decision making regarding GG1. Relabeling (ie, avoiding word “cancer”) increases proclivity for AS and would likely improve public health.
Current status and challenges in prenatal and neonatal screening, diagnosis, and management of congenital heart disease in China
Authors: Yingying Zhang, Jingyi Wang, Jianxin Zhao, Guoying Huang, Kaibo Liu, Wei Pan, Luming Sun, Jun Li, Wenli Xu, Chunhua He, Yunting Zhang, Shoujun Li, Hao Zhang, Jun Zhu, Yihua He
Journal: The Lancet Child & Adolescent Health (2023)
SARS-CoV-2 targets the liver and manipulates glucose metabolism
Authors: Carlos J. Pirola, Silvia Sookoian
Journal: Trends in Molecular Medicine (2023)

A recent publication by Barreto and colleagues showed that SARS-CoV-2 directly triggers hyperglycemia by infecting hepatocytes and inducing phosphoenolpyruvate carboxykinase (PEPCK)-dependent gluconeogenesis. Here, we discuss the biological importance of these findings, including the hepatic tropism of SARS-CoV-2. We also comment on the clinical implications of the bidirectional connection between COVID-19 and noncommunicable diseases.
Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach
Authors: Matthew Greenhawt, Timothy E. Dribin, Elissa M. Abrams, Marcus Shaker, Derek K. Chu, David B.K. Golden, Cem Akin, Akterini Anagnostou, Faisal ALMuhizi, Waleed Alqurashi, Peter Arkwright, James L. Baldwin, Aleena Banerji, Philippe Bégin, Moshe Ben-Shoshan, Jonathan Bernstein, Theresa A. Bingemann, Carsten Bindslev-Jensen, Kim Blumenthal, Aideen Byrne, Julia Cahill, Scott Cameron, Dianne Campbell, Ronna Campbell, Michael Cavender, Edmond S. Chan, Sharon Chinthrajah, Pasquale Comberiati, Jacqueline J. Eastman, Anne K. Ellis, David M. Fleischer, Adam Fox, Pamela A. Frischmeyer-Guerrerio, Remi Gagnon, Lene H. Garvey, Mitchell H. Grayson, Ghislaine Annie Clarisse Isabwe, Nicholas Hartog, David Hendron, Caroline C. Horner, Johnathan O'B Hourihane, Edward Iglesia, Manstein Kan, Blanka Kaplan, Constance H. Katelaris, Harold Kim, John M. Kelso, David A. Khan, David Lang, Dennis Ledford, Michael Levin, Jay A. Lieberman, Richard Loh, Douglas P. Mack, Bruce Mazer, Ketan Mody, Gisele Mosnaim, Daniel Munblit, S. Shahzad Mustafa, Anil Nanda, Richard Nathan, John Oppenheimer, Iris M. Otani, Miguel Park, Ruby Pawankar, Kirsten P. Perrett, Jonny Peter, Elizabeth J. Phillips, Matthieu Picard, Mitchell Pitlick, Allison Ramsey, Trine Holm Rasmussen, Melinda M. Rathkopf, Hari Reddy, Kara Robertson, Pablo Rodriguez del Rio, Stephen Sample, Ajay Sheshadri, Javed Sheik, Sayantani B. Sindher, Jonathan M. Spergel, Cosby A. Stone, David Stukus, Mimi L.K. Tang, James M. Tracy, Paul J. Turner, Timothy K. Vander Leek, Dana V. Wallace, Julie Wang, Susan Wasserman, David Weldon, Anna R. Wolfson, Margitta Worm, Mona-Rita Yacoub
Journal: Journal of Allergy and Clinical Immunology (2023)
Cu Aerogels with Sustainable Cu(I)/Cu(II) Redox Cycles for Sensitive Nonenzymatic Glucose Sensing
Authors: Qie Fang, Hengjia Wang, Xiaoqian Wei, Yinjun Tang, Xin Luo, Weiqing Xu, Liuyong Hu, Wenling Gu, Chengzhou Zhu
Journal: Advanced Healthcare Materials (2023)

Abstract Developing functional nanomaterials for nonenzymatic glucose electrochemical sensing platforms is vital and challenging from the perspective of pathology and physiology. Accurate identification of active sites and thorough investigation of catalytic mechanisms are critical prerequisites for the design of advanced catalysts for electrochemical sensing. Herein, Cu aerogels are synthesized as a model system for sensitive nonenzymatic glucose sensing. The resultant Cu aerogels exhibit good catalytic activity for glucose electrooxidation with high sensitivity and a low detection limit. Significantly, in situ electrochemical investigations and Raman characterizations reveal the catalytic mechanism of Cu‐based nonenzymatic glucose sensing. During the electrocatalytic oxidation of glucose, Cu(I) is electrochemically oxidized to generate Cu(II), and the resultant Cu(II) is spontaneously reduced back to Cu(I) by glucose, achieving the sustained Cu(I)/Cu(II) redox cycles. This study provides profound insights into the catalytic mechanism for nonenzymatic glucose sensing, which provides great potential guidance for a rational design of advanced catalysts in the future.
The Importance of Professional Societies as Academic Homes
Authors: Peter S. Liang, Sarah F. Andres, Ryan B. Perumpail, Raj Shah, Alexandra T. Strauss, Stephanie Pointer
Journal: Clinical Gastroenterology and Hepatology (2023)

We met as members of the Trainee and Early Career Committee of the American Gastroenterological Association (AGA). Our mutual experiences as trainees were followed by divergent career paths as academic clinicians, private practitioners, and research scientists. Along this journey, we gained a deep appreciation for the way that professional societies can unite people with different backgrounds and expertise and enhance our career trajectories. In this article, we share our thoughts on the importance of societies in our professional lives and practical advice about how trainees can become involved.
DMT310, a novel once-weekly topical treatment for patients with moderate-to-severe acne vulgaris: Results of a phase 2b randomized, double-blind, placebo-controlled trial
Authors: Lawrence F. Eichenfield, Janet C. DuBois, Michael H. Gold, Christopher J. Nardo, Zoe D. Draelos, E. Armas, O. DeValle, R.S. Haber, T. Jones, S.E. Kempers, T.G. Knoepp, B.J. Kuttner, R. Lieberman, M.L. Miller, D.M. Stewart, J. Weinberg
Journal: Journal of the American Academy of Dermatology (2023)

Poor patient adherence with antiacne medications is a common clinical challenge. DMT310, a natural, topical product with a once-weekly application schedule, may alleviate this obstacle.Evaluate the safety, tolerability, and efficacy of DMT310 in treating moderate-to-severe acne.This 12-week, randomized, double-blind, placebo-controlled, multicenter clinical trial enrolled participants 12 years and older with moderate-to-severe acne.The intent-to-treat population included a total of 181 participants (DMT310, N = 91; placebo, N = 90). Participants who received DMT310 vs participants treated with placebo demonstrated a statistically significant greater reduction in the number of inflammatory and noninflammatory lesions at all time points: inflammatory lesion counts at week 12 (-15.64 vs -10.84, P < .001); noninflammatory lesion counts at week 12 (-18.26 vs -12.41, P < .001). DMT310-treated participants also had higher rates of Investigator's Global Assessment treatment success than participants in the placebo group at all time points: Investigator's Global Assessment at week 12 (44.40% vs 17.78%; P < .001). No serious treatment related adverse events occurred.DMT310 once-weekly topical treatment significantly reduced both inflammatory and noninflammatory lesions and yielded a greater proportion of Investigator's Global Assessment treatment success at all time points in participants with moderate-to-severe acne.
Flashback Foreword: Human Papillomavirus and Incidence and Survival of Oropharyngeal Cancers
Authors: Maura L. Gillison
Journal: Journal of Clinical Oncology (2023)

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States. June 07, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00224 Journal of Clinical Oncology - published online before print June 7, 2023 PMID: 37285652 Flashback Foreword: Human Papillomavirus and Incidence and Survival of Oropharyngeal Cancers Maura L. Gillison, MD, PhD1,2xMaura L. GillisonSearch for articles by this author Show More 1Associate Editor, Journal of Clinical Oncology, Alexandria, VA2University of Texas MD Anderson Cancer Center, Houston, TX https://doi.org/10.1200/JCO.23.00224 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2011, Chaturvedi et al1 were the first to identify human papillomavirus infection as the cause of rising oropharyngeal cancer incidence and improvements in survival in the United States. The article had immediate implications for the primary and secondary prevention of head and neck cancers.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Human Papillomavirus and Incidence and Survival of Oropharyngeal CancersThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Maura L. GillisonThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: Bristol Myers Squibb, Merck, EMD Serono, BioNTech, Shattuck Labs, Bayer, Debiopharm Group, Ipsen, Gilead Sciences, Bicara Therapeutics, Nektar, Istari, LLX Solutions, OncLive, Seattle Genetics, Kura Oncology, Mirati Therapeutics, Sensei Biotherapeutics, Eisai, Exelixis, ITeos Therapeutics, Caladrius BiosciencesResearch Funding: Bristol Myers Squibb (Inst), Genocea Biosciences (Inst), Cullinan Oncology (Inst), Genentech (Inst), Agenus (Inst), Kura Oncology (Inst)No other potential conflicts of interest were reported. Companion Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
Optimal Threshold of FEV<sub>t</sub>/FVC Ratio for Detection of Airflow Limitation Associated with Structural Lung Disease
Authors: Surya P. Bhatt, Arie Nakhmani, Carla G. Wilson, Sandeep Bodduluri
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

"Optimal Threshold of FEVt/FVC Ratio for Detection of Airflow Limitation Associated with Structural Lung Disease." American Journal of Respiratory and Critical Care Medicine, 208(4), pp. 498–501
Editorial Board
Authors: G Attard, J Tabernero, A Cervantes, F André, C Sotiriou, J Vansteenkiste, S Yano, A Chan, S Pignata, G Long, K Tsukasaki, K Jordan, C Swanton, N Mcgranahan, C Massard, P Garrido, K Dhingra, V Moreno, L Rowett, P Bernasconi, S Hoskin
Journal: Annals of Oncology (2023)
Table of Contents
Authors: V Subbiah, S Pant, K Pomykala, B Hadaschik, O Sartor, S Gillessen, C Sweeney, T Maughan, K Herrmann, A Spreafico, A Heirali, D Araujo, T Tan, M Oliva, P Schneeberger, B Chen, M Wong, L.-A Stayner, A Hansen, S Saibil, B Wang, K Cochrane, K Sherriff, E Allen-Vercoe, W Xu, L Siu, B Coburn, O Gluz, S Kuemmel, U Nitz, M Braun, K Lüdtke-Heckenkamp, R Von Schumann, M Darsow, H Forstbauer, J Potenberg, C Uleer, E Grischke, B Aktas, C Schumacher, C Zu Eulenburg, R Kates, K Jó, M Graeser, R Wuerstlein, R Baehner, M Christgen, H Kreipe, N Harbeck, J Ros, J Matito, G Villacampa, R Comas, A Garcia, G Martini, I Baraibar, N Saoudi, F Salvà, Á Martin, M Antista, R Toledo, E Martinelli, F Pietrantonio, A Boccaccino, C Cremolini, R Dientsmann, J Tabernero, A Vivancos, E Elez, G Liposits, S Arora, N Battisti, E Soto-Perez-De-Celis, K Loh, G Williams
Journal: Annals of Oncology (2023)
Cascaded Nanozyme with In Situ Enhanced Photothermal Capacity for Tumor‐Specific and Self‐Replenishing Cancer Therapy
Authors: Xiaoli Cai, Renyu Liu, Hongye Yan, Lei Jiao, Meng Sha, Yifeng Chen, Shuang Rong, Zhengzheng Liu, Liu Deng, Liangfang Shen, Chengzhou Zhu
Journal: Advanced Healthcare Materials (2023)

Reactive oxygen species (ROS)-involved tumor therapeutic strategy, chemodynamic therapy (CDT), has attracted extensive research interest in the scientific community. However, the therapeutic effect of CDT is insufficient and unsustainable owing to the limited endogenous H2 O2 level in the tumor microenvironment. Here, peroxidase (POD)-like RuTe2 nanozyme with the immobilization of glucose oxidase (GOx) and allochroic 3,3',5,5'-tetramethylbenzidine (TMB) molecule have been synthesized to construct RuTe2 -GOx-TMB nanoreactors (RGT NRs) as cascade reaction systems for tumor-specific and self-replenishing cancer therapy. GOx in sequential nanocatalysts can effectively deplete glucose in tumor cells. Meanwhile, a sustainable supply of H2 O2 for subsequent Fenton-like reactions catalyzed by RuTe2 nanozyme is achieved in response to the mild acidic tumor microenvironment. Through this cascade reaction, highly toxic hydroxyl radicals (·OH) are produced, which can further oxidize TMB to trigger tumor-specific "turn-on" photothermal therapy (PTT). In addition, PTT and massive ROS can stimulate the tumor immune microenvironment and activate the systematic anti-tumor immune responses, exerting a notable effect on hindering tumor recurrence and metastasis. This study paves a promising paradigm for synergistic starvation therapy, PTT, and CDT cancer therapy with high efficiency.